title: Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
authors.affiliation: Department of Experimental Immunology, Academic Medical Center, University of Amsterdam Department of Hematology, Academic Medical Center, University of Amsterdam.
authors.forename: Rachel
authors.initials: R
authors.lastname: Thijssen
authors.affiliation: Department of Experimental Immunology, Academic Medical Center, University of Amsterdam Department of Hematology, Academic Medical Center, University of Amsterdam.
authors.forename: Erik
authors.initials: E
authors.lastname: Slinger
authors.affiliation: Department of Experimental Immunology, Academic Medical Center, University of Amsterdam.
authors.forename: Katinka
authors.initials: K
authors.lastname: Weller
authors.affiliation: Department of Experimental Immunology, Academic Medical Center, University of Amsterdam.
authors.forename: Christian R
authors.initials: CR
authors.lastname: Geest
authors.affiliation: AIMM Therapeutics, Amsterdam.
authors.forename: Tim
authors.initials: T
authors.lastname: Beaumont
authors.affiliation: Department of Hematology, Academic Medical Center, University of Amsterdam Lymphoma and Myeloma Center Amsterdam, LYMMCARE, The Netherlands.
authors.forename: Marinus H J
authors.initials: MH
authors.lastname: van Oers
authors.affiliation: Department of Hematology, Academic Medical Center, University of Amsterdam Lymphoma and Myeloma Center Amsterdam, LYMMCARE, The Netherlands.
authors.forename: Arnon P
authors.initials: AP
authors.lastname: Kater
authors.affiliation: Department of Experimental Immunology, Academic Medical Center, University of Amsterdam Lymphoma and Myeloma Center Amsterdam, LYMMCARE, The Netherlands e.eldering@amc.uva.nl.
authors.forename: Eric
authors.initials: E
authors.lastname: Eldering
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors; D000069283:Rituximab / Q000627:therapeutic use*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D059016:Tumor Microenvironment / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D047428:Protein Kinase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D013449:Sulfonamides; D000069283:Rituximab; C579720:venetoclax
keywords: ABT-199; CD20 antibodies; chronic lymphocytic leukemia; kinase inhibitors; resistance